This does not invalidate the findings but adds a potential source of bias Single-blind only: While the investigator assessing photos was blinded, patients knew whether they received the active serum or saline, which could influence self-reported satisfaction scores No long-term follow-up: The study ended at 6 months
The body processes Wegovy through natural metabolic pathways, primarily involving proteolytic degradation and beta-oxidation, with metabolites excreted via both urine and faeces, similar to the processing of endogenous proteins
Instead, we use forms that are already biologically active and ready for cellular use
Side effects are typically mild, temporary, and manageable
But regulatory approvals are never guaranteed, and unexpected safety signals can delay or derail the process
On the basis of the results, no clinically relevant change in the tolerability and safety profiles of semaglutide, metformin, warfarin, atorvastatin or digoxin is anticipated when co-dosing at steady state